ArticleThe Journal of clinical investigation1997
Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats.
Article in The Journal of clinical investigation, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 173 citations in OpenAlex.
- Glucagon-Like Peptide Receptor-1 Agonists Used for Medically-Supervised Weight Loss in Patients With Hip and Knee Osteoarthritis: Critical Considerations for the Arthroplasty Surgeon.Arthroplasty today · 2024Article
- Pancreatic beta-cell mass and function and therapeutic implications of using antidiabetic medications in type 2 diabetes.Journal of diabetes investigation · 2024Review
- Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists.Frontiers in endocrinology · 2024Review
- Review
- Research Progress on Hypoglycemic Mechanisms of Resistant Starch: A Review.Molecules (Basel, Switzerland) · 2022Review
- Mitofusins Mfn1 and Mfn2 Are Required to Preserve Glucose- but Not Incretin-Stimulated β-Cell Connectivity and Insulin Secretion.Diabetes · 2022Article
- Novel Insights into the Roles and Mechanisms of GLP-1 Receptor Agonists against Aging-Related Diseases.Aging and disease · 2022Review
- The Potential Roles of Probiotics, Resistant Starch, and Resistant Proteins in Ameliorating Inflammation during Aging (Inflammaging).Nutrients · 2022Review
- Sitagliptin Increases Beta-Cell Function and Decreases Insulin Resistance in Newly Diagnosed Vietnamese Patients with Type 2 Diabetes Mellitus.Diabetes, metabolic syndrome and obesity : targets and therapy · 2020Article
- Muscle cannabinoid 1 receptor regulates Il-6 and myostatin expression, governing physical performance and whole-body metabolism.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Article
- Insulin Is Transcribed and Translated in Mammalian Taste Bud Cells.Endocrinology · 2018Article
- Blockade of cannabinoid 1 receptor improves glucose responsiveness in pancreatic beta cells.Journal of cellular and molecular medicine · 2018Article
- Laminarin counteracts diet-induced obesity associated with glucagon-like peptide-1 secretion.Oncotarget · 2017Article
- GLP-1 receptor independent pathways: emerging beneficial effects of GLP-1 breakdown products.Eating and weight disorders : EWD · 2017Review
- Blockade of cannabinoid 1 receptor improves GLP-1R mediated insulin secretion in mice.Molecular and cellular endocrinology · 2016Article
- The L-Cell in Nutritional Sensing and the Regulation of Appetite.Frontiers in nutrition · 2015Review
- Therapeutic Approaches for Preserving or Restoring Pancreatic β-Cell Function and Mass.Diabetes & metabolism journal · 2014Review
- Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2014Article
- Diminished mTOR signaling: a common mode of action for endocrine longevity factors.SpringerPlus · 2014Review
- Age-related impairment of pancreatic Beta-cell function: pathophysiological and cellular mechanisms.Frontiers in endocrinology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Wistar rats develop glucose intolerance and have a diminished insulin response to glucose with age. The aim of this study was to investigate if these changes were reversible with glucagon-like peptide-1 (GLP-1), a peptide that we have previously shown could increase insulin mRNA and total insulin content in insulinoma cells. We infused 1.5 pmol/ kg-1.min-1 GLP-1 subcutaneously using ALZET microosmotic pumps into 22-mo-old Wistar rats for 48 h. Rat infused with either GLP-1 or saline were then subjected to an intraperitoneal glucose (1 g/kg body weight) tolerance test, 2 h after removing the pump. 15 min after the intraperitoneal glucose, GLP-1-treated animals had lower plasma glucose levels (9.04+/-0.92 mmol/liter, P < 0.01) than saline-treated animals (11.61+/-0.23 mmol/liter). At 30 min the plasma glucose was still lower in the GLP-1-treated animals (8.61+/-0.39 mmol/liter, P < 0.05) than saline-treated animals (10.36+/-0.43 mmol/liter). This decrease in glucose levels was reflected in the higher insulin levels attained in the GLP-1-treated animals (936+/-163 pmol/liter vs. 395+/-51 pmol/liter, GLP-1 vs. saline, respectively, P < 0.01), detected 15 min after glucose injection. GLP-1 treatment also increased pancreatic insulin, GLUT2, and glucokinase mRNA in the old rats. The effects of GLP-1 were abolished by simultaneous infusion of exendin [9-39], a specific antagonist of GLP-1. GLP-1 is therefore able to reverse some of the known defects that arise in the beta cell of the pancreas of Wistar rats, not only by increasing insulin secretion but also by inducing significant changes at the molecular level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.